…The drugs DNAPrint Pharmaceuticals Inc. intends to bring to the market will be theragnostic products – predictive test/drug combinations. Performance will be optimized for specific patient populations; the test is used to identify which patients have the highest likelihood of gaining therapeutic benefit and/or avoiding side effects, and the drug would be administered to only these patients. Compared with blockbusters, our drugs will be taken by fewer patients and will be less profitable. However, while a traditional pharmaceutical company may create one drug to treat a given market, we might produce several to treat the segmented components of this market, with a net gain in overall performance. We expect that the tailoring of drug development to optimally receptive subpopulations will result in faster, more efficient, more economical and less risky clinical trials, resulting in fewer company-killing failures, better patient outcomes, reduced litigation expenses and, overall, project pharmaceutical companies adhering to a higher ethical standards than many consumers believe pharmaceutical companies typically achieve….
…Our PT-500 series comprise three related compounds (PT-501, PT-502 and PT-503) being developed for attention deficit and hyperactivity disorder, drug addiction and depression, respectively. Early preclinical animal models show that the compounds are selective, with a high degree of activity when compared side by side with competing compounds, such as serotonin-reuptake inhibitors. Our PT-200 series of compounds are Phase III candidates licensed from our German partner, Biofrontera, for ocular and nasal allergies, and are designed to provide a revenue and corporate-development bridge to the company …
Excerpts from Future medicine Pharmacogenomics 2008, Vol. 9, No. 2, Pages 247-251 (doi:10.2217/14622416.9.2.247) Special Report DNAPrint Genomics, Inc.: better drugs for segmented markets
Market Data 
Markets 
AI
